Effect of a structurally modified human granulocyte colony stimulating factor, G-CSFa, on leukopenia in mice and monkeys
© Jiang et al; licensee BioMed Central Ltd. 2011
Received: 29 April 2011
Accepted: 13 June 2011
Published: 13 June 2011
Granulocyte colony stimulating factor (G-CSF) regulates survival, proliferation, and differentiation of neutrophilic granulocyte precursors, Recombinant G-CSF has been used for the treatment of congenital and therapy-induced neutropenia and stem cell mobilization. Due to its intrinsic instability, recombinant G-CSF needs to be excessively and/or frequently administered to patients in order to maintain a plasma concentration high enough to achieve therapeutic effects. Therefore, there is a need for the development of G-CSF derivatives that are more stable and active in vivo.
Using site-direct mutagenesis and recombinant DNA technology, a structurally modified derivative of human G-CSF termed G-CSFa was obtained. G-CSFa contains alanine 17 (instead of cysteine 17 as in wild-type G-CSF) as well as four additional amino acids including methionine, arginine, glycine, and serine at the amino-terminus. Purified recombinant G-CSFa was tested for its in vitro activity using cell-based assays and in vivo activity using both murine and primate animal models.
In vitro studies demonstrated that G-CSFa, expressed in and purified from E. coli, induced a much higher proliferation rate than that of wild-type G-CSF at the same concentrations. In vivo studies showed that G-CSFa significantly increased the number of peripheral blood leukocytes in cesium-137 irradiated mice or monkeys with neutropenia after administration of clyclophosphamide. In addition, G-CSFa increased neutrophil counts to a higher level in monkeys with a concomitant slower declining rate than that of G-CSF, indicating a longer half-life of G-CSFa. Bone marrow smear analysis also confirmed that G-CSFa was more potent than G-CSF in the induction of granulopoiesis in bone marrows of myelo-suppressed monkeys.
G-CSFa, a structurally modified form of G-CSF, is more potent in stimulating proliferation and differentiation of myeloid cells of the granulocytic lineage than the wild-type counterpart both in vitro and in vivo. G-CSFa can be explored for the development of a new generation of recombinant therapeutic drug for leukopenia.
Granulocyte colony stimulating factor (G-CSF) is the principal cytokine that regulates survival, proliferation, and differentiation of neutrophilic granulocyte precursors [1–3], and it functionally activates mature blood neutrophils as well [4–7]. Among the family of colony-stimulating factors, G-CSF is the predominant inducer of terminal differentiation of granulocytes . Recombinant human G-CSF has been used as a therapeutic drug for leukopenia of cancer patients who receive myelo-suppressive radio-or chemotherapy [9, 10]. In recent years, recombinant G-CSF has also been used for the treatment of congenital neutropenia and stem cell mobilization [11, 12]. It has been more than fifteen years since recombinant G-CSF was successfully used in the clinics. Due to its intrinsic instability, G-CSF needs to be excessively and/or frequently administered to patients in order to maintain a plasma concentration high enough to achieve therapeutic effects. This administration regimen not only causes inconvenience and pains in patients but also increases the chance for infections. Therefore, there is a necessity for the development of G-CSF derivatives that are more stable and active in vivo. Here, we report that G-CSFa, a recombinant G-CSF derivative, exhibits potent biological activities both in vivo and in vitro and that these activities appear to result from an enhanced stability of modified G-CSF and its binding affinity to the cognate receptor.
Male BALB/CICR C57 mice with an average weight of 22.5 ± 1.2 g (20.0 ~ 24.9 g), and monkeys with an average weight of (5.4 ± 1.0 kg) were selected for our studies. Animals were housed in individual stainless steel cages in a study room with a regulated temperature of 24 ± 2°C, relative humidity of 50 ± 10%, and a 12-h light cycle. All animal experiments were conducted in compliance with the Guidelines for Animal Experimentation issued by the Chinese Association for Laboratory Animal Science and the Standards Relating to the Care and Management of Experimental Animals throughout the study.
Mutant G-CSF and Expression of G-CSFa in E. Coli
G-CSF cDNA was obtained through reverse transcriptase-mediated polymerase chain reaction (RT-PCR) using total RNAs isolated from human monocytes. The primers used for PCR were as follows: upstream primer, 5' TGG ATC CAT GAC CCC CCT GGG CCC 3' and downstream primer, 5' TAA GAT CTC AAG CTT TCA GGG CTG CGC AAG GTG GCG TA3'. The amplified products were fractionated on agarose gels. The G-CSF cDNA eluted from the agarose gel was digested by Bam HI and Hind III, and ligated to plasmid pQE3 that had been cut with the same restriction enzymes. The ligation mixture was transformed into Escherichia coli JM109 competent cells for characterization of the cloned cDNA. Mutant G-CSF (G-CSFC17A) was made by replacing codon TGC with codon GCC through site-direct mutagenesis. The identity of G-CSF cDNA, as well as the introduced mutation, was confirmed by a thorough DNA sequencing analysis. The pQE3 plasmid expressing mutant G-CSF (G-CSFa) was transformed into E. coli M15 cells for expression. Expression of G-CSFa was induced by isopropylthio-β-d-galactoside (IPTG).
Refolding and purification of G-CSFa
E. Coli pellets were disrupted with addition of lysozyme (5 mg/liter culture) in 0.1 M TrisHCl buffer (pH 8.0). Inclusion body was collected by washing three times with an extraction buffer [50 mM TrisHCl (pH 8.0), 2 mM EDTA, 2 M urea] and it was dissolved in a buffer containing a high concentration of urea [50 mM TrisHCl (pH 8.0), 2 mM EDTA, 8 M urea, 2% DTT]. Refolding of recombinant G-CSFa was achieved by dialysis against 50 mM TrisHCl buffer (pH 8.0) for three times (12 h intervals). Refolded recombinant G-CSFa was purified by anion exchange chromatography and size exclusion chromatography. Recombinant G-CSFa was stored in 50 mM acetic acid-sodium acetate buffer (pH 5.4) containing 5% mannitol. Purified protein was also subjected to protein sequencing analysis using the Edman degradation method .
Protein samples fractionated on denaturing (SDS) polyacrylamide gels (4% stacking gel, 12% separating gel) were transferred to a polyvinylidene difluoride (PVDF) membrane. The membrane was blocked in a 2% bovine serum albumin (BSA) solution for 1 hr and then incubated for 1 hr with a monoclonal antibody to G-CSF (R & D systems). After washing three times with a TrisHCl buffer, the membrane was incubated for 1 hr with a goat-anti-mouse immunoglobulin G (IgG) conjugated with alkaline phosphatase. Specific signals on the membrane were visualized by addition of substrate, O-phenylene diamine (OPD).
In vitro bioactivity assay
In vitro activity of recombinant G-CSFa was determined using the murine myelobalstic cell line NFS-60 as originally described by Shirafuji . We also employed this bioassay method as described above for measuring the activity of human G-CSF using NFS-60 cells. Recombinant G-CSF made in house as well as commercial one were used as positive controls.
Animal neutropenia models
BALB/CICR C57 male mice with an average weight of 22.5 ± 1.2 g were irradiated with cesium-137 (4 Gy) using Gammacell-40 apparatus (Nurolion, Canada) to induce leukopenia. To induce leukopenia in Monkeys, animals were intravenously administered with cyclophosphamide at a dose of 50 mg/kg/day for 2 days.
Measurement of mice bone marrow DNA content
Mouse femur was cleaned and washed with 5 mM CaCl2. Bone marrow cells were flushed out with a 10 ml 5 mM CaCl2 solution. Bone marrow cells were placed at 4°C for 30 min and then centrifuged (2,500 RPM × 15 min). The pellet was resuspended in 5 ml 0.2 M HClO, heated at 90°C for 15 min, and filtrated through a 0.45 μm filter after cooling. DNA content was determined by measuring the absorbance of the solution at 260 nm (A260nm) in a spectrophotometer.
Monkey bone marrow was aspirated from the posterior iliac crest. Bone marrow slides were prepared in a fashion similar to the blood smears, which were subjected to routine Wright's staining. Peripheral white blood cells and neutrophils were counted using an automated hematology cell counter (Biochem Immunosystem).
Data obtained from mouse studies were subjected to statistical analysis using a Q test. Data obtained from monkey studies were subjected to statistical analysis using a Newman-Keuls test. The results were considered statistically significant when P value was less than 0.05.
Effect of G-CSFa on white blood cell counts in irradiated C57 Mice (109/L; x ± SD; n = 12)
Days After Irradiation
11413 ± 2089
1233 ± 553
2450 ± 1104
2533 ± 850
3342 ± 811
5083 ± 260
7925 ± 1667
7575 ± 1858
8750 ± 2203
Wt G-CSF (50 mg/kg)
10996 ± 2731
1342 ± 337
3100 ± 1408
2667 ± 502
6358 ± 1398
9858 ± 2333a
14650 ± 2861b
11092 ± 2319a
10592 ± 1547
G-CSFa (25 mg/kg)
11083 ± 2724
855 ± 342
2508 ± 923
1900 ± 972
5483 ± 973
8192 ± 2721
11192 ± 4593a
12917 ± 2921b
10533 ± 1741
G-CSFa (50 mg/kg)
10178 ± 4014
1100 ± 412
2042 ± 687
2508 ± 565
5325 ± 1139
9250 ± 3766a
10975 ± 3052a
13950 ± 3087b
13075 ± 3120a
G-CSFa (100 mg/kg)
11814 ± 3802
1175 ± 344
2783 ± 1233
4483 ± 1394
6325 ± 1726
13467 ± 4719b
15650 ± 3572b
15700 ± 4278b
13383 ± 2696
DNA content of mouse bone marrow cells
0.65 + 0.12
Wt G-CSF (50 μg/kg)
1.01 + 0.34*
G-CSFa (25 μg/kg)
0.95 + 0.13*
G-CSFa (50 μg/kg)
1.01 + 0.14*
G-CSFa (100 μg/kg)
1.02 + 0.20*
G-CSF is a glycoprotein with a molecular mass of approximate 20 kDa. It is a bioactive molecule that has been extensively used in the clinic as a therapeutic agent for supporting the production of blood cells of the neutrophil linage . It also displays biological effects on various aspects of hematopoiesis both in vivo and in vitro . G-CSF has widely used in the clinic for over 15 years, primarily for accelerating neutrophil recovery in cancer patients with myelo-suppressive chemotherapy or radiotherapy [9, 10]. G-CSF is a glycoprotein although glycosylation is not essential for its bioactivity. Clinical studies have demonstrated that recombinant non-glycosylated G-CSF expressed in and purified from E. coli displays almost the same therapeutic efficacy as glycosylated form of G-CSF [11, 16]. Native G-CSF contains five cysteine residues. They form two internal disulfide bonds (Cys36-Cys42 and Cys64-Cys74), leaving one cysteine residue (Cys17) with a free sulfhydryl group. It is conceivable that this free cysteine residue may pose some problems during G-CSF purification and refolding. Firstly, the presence of Cys17 may increase the frequency of mismatch during the formation of intra-molecular disulfide bonds, resulting in a reduced yield of refolding. Secondly, it is possible that the free sulfhydryl group in cysterine residues may interfere with the stability of G-CSF. In other words, Cys17 may form inter-molecular disulfide bonds, resulting in the formation of G-CSF oligomers under certain oxidized condition. Oligomerization can conceivably lead to a decrease in the availability of G-CSF.
We reason that the substitution of cysteine 17 with alanine may result in an enhanced bioavailability and bioactivity of G-CSF, possibly through the elimination of oligomerization caused by the formation of inter-molecular disulfide bonds. In fact, our cell-based assays and in vivo studies in both mice and monkeys are consistent with the notion. Significantly, as evidenced from the examination of the first peak of neutrophil increase (Figure 5), G-CSFa induced a much higher level of ANC than G-CSF did. Although it is relative small this increase is of great value for patients receiving myelo-suppressive therapies. It is the period when patients are most susceptible to infections due to drastic neutrophil reduction. Therefore, a shortened window in which patients have low neutrophil counts will greatly facilitate them to combat deleterious infections. Further supporting this notion, a separate pharmacokinetic study reveals that G-CSFa exhibits both better stability in vitro and higher bioavailability in vivo than wild-type G-CSF .
G-CSF exerts its activity through the interaction with its receptor (G-CSF-R). Upon binding to G-CSF-R, G-CSF induces a signal transduction cascade in target cells, leading to various biological manifestations including cell proliferation and differentiation. G-CSF belongs to the long chain family of cytokines with an anti-parallel 4-helix bundles and long overhand loops. The major binding site on G-CSF has been shown to include residues in A and C helices [18, 19]. Further studies indicates that Glu19 in the A helix of G-CSF molecule electrostatically inter-reacts with Arg288 of G-CSF-R [20, 21]. A recent study on the crystal structure of G-CSF, complexed with the cytokine homologous region of G-CSF-R, reveals that residues in the amino-terminus of G-CSF may act as additional contact sites with G-CSF-R, which is unstructured in the unbound protein . In this respect, the addition of arginine, glycine, and serine residues in the amino-terminus of G-CSFa that results in a more positive charge in the amino-terminus of G-CSFa may further enhance the binding between the cytokine and its receptor. This may also contribute to the higher bioactivity observed with the mutant G-CSF. It is conceivable that the tighter binding to its cognate receptor may render G-CSFa to be dissociated from its receptor at a slower rate, resulting in a longer time of action both in vivo and in vitro. In fact, G-CSF with a single amino acid substitution (Cys17 to Ala17) shows a better stability in plasma . Therefore, we believe that the same mutation in G-CSFa also contributes to the enhanced bioactivities.
During the past decade or so, great efforts have been directed to finding a more stable and thus more effective G-CSF because of its instability in vivo. PEGylated G-CSF has been reported to enhance the stability of this cytokine. However, the steric hindrance effect of PEGylated proteins significantly suppresses the specific binding of PEGylated proteins to their cognate receptors or substrates . Besides, pegylation calls for an additional modification step after obtaining purified target protein, which makes the production process inconvenient and adds costs to the production. In the current study, we report that G-CSFa exhibits an enhanced bioactivity due likely to its better stability. As a chronic toxicity study shows that G-CSFa does not exhibit significant toxicity and immunogenicity in rats , this cytokine derivative can be further explored for the development of a new generation of therapeutic agents for patients with neutropenia.
We thank Dr. Yiqi Zhou for useful discussion. This work is supported in part by grants from Ministry of Science & Technology of China (Grant # 2004AA001036), State Scientific Key Projects for New Drug Research and Development (2009ZX09102-250), and High-tech Research Project for Medicine and Pharmacology of Jiangsu province (BG20070605).
- Dong F, van Buitenen C, Pouwels K, Hoefsloot LH, Lowenberg B, Touw IP: Distinct cytoplasmic regions of the human granulocyte colony-stimulating factor receptor involved in induction of proliferation and maturation. Mol Cell Biol. 1993, 13 (12): 7774-7781.PubMed CentralView ArticlePubMedGoogle Scholar
- Souza LM, Boone TC, Gabrilove J, Lai PH, Zsebo KM, Murdock DC, Chazin VR, Bruszewski J, Lu H, Chen KK: Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells. Science. 1986, 232 (4746): 61-65. 10.1126/science.2420009.View ArticlePubMedGoogle Scholar
- Panopoulos AD, Watowich SS: Granulocyte colony-stimulating factor: molecular mechanisms of action during steady state and 'emergency' hematopoiesis. Cytokine. 2008, 42 (3): 277-288. 10.1016/j.cyto.2008.03.002.PubMed CentralView ArticlePubMedGoogle Scholar
- Bober LA, Grace MJ, Pugliese-Sivo C, Rojas-Triana A, Waters T, Sullivan LM, Narula SK: The effect of GM-CSF and G-CSF on human neutrophil function. Immunopharmacology. 1995, 29 (2): 111-119. 10.1016/0162-3109(94)00050-P.View ArticlePubMedGoogle Scholar
- de Haas M, Kerst JM, van der Schoot CE, Calafat J, Hack CE, Nuijens JH, Roos D, van Oers RH, von dem Borne AE: Granulocyte colony-stimulating factor administration to healthy volunteers: analysis of the immediate activating effects on circulating neutrophils. Blood. 1994, 84 (11): 3885-3894.PubMedGoogle Scholar
- Gottlieb RA, Giesing HA, Zhu JY, Engler RL, Babior BM: Cell acidification in apoptosis: granulocyte colony-stimulating factor delays programmed cell death in neutrophils by up-regulating the vacuolar H(+)-ATPase. Proc Natl Acad Sci USA. 1995, 92 (13): 5965-5968. 10.1073/pnas.92.13.5965.PubMed CentralView ArticlePubMedGoogle Scholar
- Lopez AF, Williamson DJ, Gamble JR, Begley CG, Harlan JM, Klebanoff SJ, Waltersdorph A, Wong G, Clark SC, Vadas MA: Recombinant human granulocyte-macrophage colony-stimulating factor stimulates in vitro mature human neutrophil and eosinophil function, surface receptor expression, and survival. J Clin Invest. 1986, 78 (5): 1220-1228. 10.1172/JCI112705.PubMed CentralView ArticlePubMedGoogle Scholar
- Basu S, Dunn A, Ward A: G-CSF: function and modes of action (Review). Int J Mol Med. 2002, 10 (1): 3-10.PubMedGoogle Scholar
- Aso Y, Akaza H: Effect of recombinant human granulocyte colony-stimulating factor in patients receiving chemotherapy for urogenital cancer. Urological rhG-CSF Study Group. J Urol. 1992, 147 (4): 1060-1064.PubMedGoogle Scholar
- Schmidberger H, Hess CF, Hoffmann W, Reuss-Borst MA, Bamberg M: Granulocyte colony-stimulating factor treatment of leucopenia during fractionated radiotherapy. Eur J Cancer. 1993, 29A (14): 1927-1931.View ArticlePubMedGoogle Scholar
- Carlsson G, Ahlin A, Dahllof G, Elinder G, Henter JI, Palmblad J: Efficacy and safety of two different rG-CSF preparations in the treatment of patients with severe congenital neutropenia. Br J Haematol. 2004, 126 (1): 127-132. 10.1111/j.1365-2141.2004.05008.x.View ArticlePubMedGoogle Scholar
- Kroger N, Zander AR: Dose and schedule effect of G-GSF for stem cell mobilization in healthy donors for allogeneic transplantation. Leuk Lymphoma. 2002, 43 (7): 1391-1394. 10.1080/10428190290033323.View ArticlePubMedGoogle Scholar
- Edman P: Sequence determination. Mol Biol Biochem Biophys. 1970, 8: 211-255.PubMedGoogle Scholar
- Shirafuji N, Asano S, Matsuda S, Watari K, Takaku F, Nagata S: A new bioassay for human granulocyte colony-stimulating factor (hG-CSF) using murine myeloblastic NFS-60 cells as targets and estimation of its levels in sera from normal healthy persons and patients with infectious and hematological disorders. Exp Hematol. 1989, 17 (2): 116-119.PubMedGoogle Scholar
- Komrokji RS, Lyman GH: The colony-stimulating factors: use to prevent and treat neutropenia and its complications. Expert Opin Biol Ther. 2004, 4 (12): 1897-1910. 10.1517/147125184.108.40.2067.View ArticlePubMedGoogle Scholar
- Chamorey AL, Magne N, Pivot X, Milano G: Impact of glycosylation on the effect of cytokines. A special focus on oncology. Eur Cytokine Netw. 2002, 13 (2): 154-160.PubMedGoogle Scholar
- Liu XX, Jiang YP: Pharmacokinetic study of a novel recombinant human granulocyte colony-stimulating factor in rats. Chin Med Sci J. 2010, 25 (1): 13-19. 10.1016/S1001-9294(10)60014-4.View ArticlePubMedGoogle Scholar
- Reidhaar-Olson JF, De Souza-Hart JA, Selick HE: Identification of residues critical to the activity of human granulocyte colony-stimulating factor. Biochemistry. 1996, 35 (28): 9034-9041. 10.1021/bi952705x.View ArticlePubMedGoogle Scholar
- Young DC, Zhan H, Cheng QL, Hou J, Matthews DJ: Characterization of the receptor binding determinants of granulocyte colony stimulating factor. Protein Sci. 1997, 6 (6): 1228-1236. 10.1002/pro.5560060611.PubMed CentralView ArticlePubMedGoogle Scholar
- Layton JE, Hall NE, Connell F, Venhorst J, Treutlein HR: Identification of ligand-binding site III on the immunoglobulin-like domain of the granulocyte colony-stimulating factor receptor. J Biol Chem. 2001, 276 (39): 36779-36787. 10.1074/jbc.M104787200.View ArticlePubMedGoogle Scholar
- Layton JE, Shimamoto G, Osslund T, Hammacher A, Smith DK, Treutlein HR, Boone T: Interaction of granulocyte colony-stimulating factor (G-CSF) with its receptor. Evidence that Glu19 of G-CSF interacts with Arg288 of the receptor. J Biol Chem. 1999, 274 (25): 17445-17451. 10.1074/jbc.274.25.17445.View ArticlePubMedGoogle Scholar
- Aritomi M, Kunishima N, Okamoto T, Kuroki R, Ota Y, Morikawa K: Atomic structure of the GCSF-receptor complex showing a new cytokine-receptor recognition scheme. Nature. 1999, 401 (6754): 713-717. 10.1038/44394.View ArticlePubMedGoogle Scholar
- Clark R, Olson K, Fuh G, Marian M, Mortensen D, Teshima G, Chang S, Chu H, Mukku V, Canova-Davis E: Long-acting growth hormones produced by conjugation with polyethylene glycol. J Biol Chem. 1996, 271 (36): 21969-21977. 10.1074/jbc.271.36.21969.View ArticlePubMedGoogle Scholar
- Xia F, Zhang QY, Jiang YP: Chronic toxicity of a novel recombinant human granulocyte colony-stimulating factor in rats. Chin Med Sci J. 2011, 26 (1): 20-27. 10.1016/S1001-9294(11)60015-1.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.